Type: Securities Fraud case filed

According to the Complaint, the Company made false and misleading statements to the market. Skechers lacked the infrastructure necessary to manage demand and sustain growth internationally. The Company instead relied on costly third-party operations solutions to manage the business. These costs would be likely to outgrow sales in the future, and international sales growth would not be likely without continued heavy expenditures. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Skechers, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. Fanhua engaged in irregular accounting and other improper business practices. These tactics were designed to overstate financial assets and performance, along with benefiting management insiders. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Fanhua, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. CV Sciences received a non-final rejection notice from the U.S. Patent Trademark Office (PTO) regarding its CVSI-007 pharmaceutical product on April 27, 2017. The PTO followed the initial non-final rejection of CVSI-007 with a final rejection on December 14, 2017. Based on these facts, the Company’s statements about its business prospects and future operations were false and materially misleading throughout the class period. When the market learned the truth about CV Sciences, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. Lannett faced a high risk of losing its exclusivity arrangement with Jerome Stevens Pharmaceuticals, which made the Company’s reported revenues not sustainable into the future. Based on that fact, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Lannett, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. Nevro developed its Senza I and II systems using proprietary and confidential trade secrets along with stolen documents fraudulently obtained from competitors. Based on this, the Company’s Senza I and II systems were neither “proprietary” nor “novel.” Nevro’s business practices made it vulnerable to legal and regulatory actions, and its sales growth was not sustainable. Based on these facts, the Company’s public statements about its business, operations, and future prospects were false and materially misleading throughout the class period. When the market learned the truth about Nevro, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. Oracle’s cloud revenues were driven in part by coercive and improper sales tactics. Examples of these practices include threatening clients with audits of non-cloud software usage if the clients did not shift software to cloud computing options. Customer support was also decreased for certain products in an effort to encourage adoption of cloud-based alternatives. Oracle’s sales teams would also threaten dramatic license cost increases if customers utilized another cloud computing provider. These tactics upset customers to the extent that some did not renew certain software licenses, or terminated business relationships with Oracle altogether. When the market learned the truth about Oracle’s business practices, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. Tesla CEO Elon Musk tweeted on August 7, 2018, “Am considering taking Tesla private at $420,” and “funding secured.” The lawsuit alleges that despite Musk’s tweets, no funding had been secured to take Tesla private at $420 per share. Musk also falsely claimed that “investor support is confirmed.” Both the SEC and Tesla’s board of directors are reportedly investigating Musk’s tweets on the matter. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Tesla, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. Tetraphase increased the number of patients enrolled in the IGNITE3 trial to 1,200 from its original 1,000 in an attempt to meet the trial’s primary endpoints. The increase in enrolled patients indicates that the existing enrolled population was not adequate to meet these endpoints. Based on these facts, the Company’s public statements about business operations and the IGNITE3 trial were false and materially misleading throughout the class period. When the market learned the truth about Tetraphase, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. Sealed Air improperly deducted $1.49 billion related to the settlement of asbestos liabilities from its taxes to artificially inflate its financial performance. The Company switched auditors to help facilitate this fraud. On August 6, 2018, the Company admitted that it had received a subpoena from the SEC related to the Company’s accounting for taxes and financial disclosures. Based on these facts, the company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Sealed Air, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. Specifically, Ampio failed to disclose that the FDA would find the Company’s AP-003-C Phase 3 clinical trial inadequate and not well-controlled. Ampio had not sufficiently completed two pivotal clinical trials for Ampion. Based on these facts, the company’s statements were false and misleading throughout the class period. When the market learned the truth about Ampio, investors suffered damages.